• Y-27632 ROCK Inhibitor: Organoid Workflow Guide

  2026-08-20

  Y-27632 enables controlled ROCK1 and ROCK2 inhibition for linking cell shape, adhesion, and stress-fiber behavior to epithelial repair assays. This guide translates a recent Treg–intestinal epithelium study into practical organoid, monolayer, and cytoskeletal workflows while separating validated findings from experimental extensions.

• Ruxolitinib, DRP1, and ATC Cell Death

  2026-08-19

  The 2024 Cell Death and Disease study identifies a previously underappreciated connection between JAK1/2-STAT3 signaling, DRP1-dependent mitochondrial fission, and regulated cell death in anaplastic thyroid carcinoma. Its in vitro and in vivo evidence indicates that ruxolitinib can promote caspase-dependent apoptosis and GSDME-mediated pyroptosis by suppressing STAT3-driven DRP1 transcription.

• Losmapimod Workflow for p38 MAPK Research

  2026-08-19

  Build reproducible inflammation, endothelial, and dephosphorylation assays around Losmapimod, also known as GW856553X. This practical guide connects selective p38α/p38β inhibition with dose design, vascular readouts, WIP1-oriented mechanistic testing, and troubleshooting.

• GOB-38 in Elizabethkingia anophelis: Study Insights

  2026-08-18

  The reference study characterizes GOB-38, a B3-Q metallo-β-lactamase from Elizabethkingia anophelis, using recombinant expression, purified-enzyme analysis, genomic investigation, and bacterial co-culture. Its broad hydrolysis profile and distinctive active-site residues help explain resistance phenotypes while highlighting why biochemical measurements must be interpreted alongside genomic and transmission evidence.

• Olaparib and the Next Layer of PARP Biology

  2026-08-18

  Olaparib (AZD2281, Ku-0059436) is more than a PARP-1/2 inhibitor for BRCA-deficient models. This thought-leadership guide connects DNA damage response assays, PAR-dependent condensate biology, and tumor radiosensitization studies to help translational researchers design more informative cancer research workflows.

• Vitamin C in HEV Organoid Assay Design

  2026-08-17

  Vitamin C and ascorbic acid can be evaluated more rigorously in hepatitis E virus organoids by separating antiviral activity from tissue toxicity. This article translates a multilineage HEV model into a practical, hypothesis-driven assay framework for cancer research and antiviral discovery.

• Formononetin Protects Neurons During Oxaliplatin Therapy

  2026-08-17

  A 2026 NeuroToxicology study identifies formononetin as a candidate for reducing oxaliplatin-induced peripheral neurotoxicity through Nrf2/HO-1 antioxidant signaling while preserving anticancer activity. Its selective activity, including limited protection against paclitaxel-related neurite damage, highlights both the promise and the boundaries of pathway-focused neuroprotection.

• DNA Replication, Membrane, and Vacuoles in E. faecalis

  2026-08-16

  Tsuchikado and colleagues show that DNA replication is closely associated with plasma-membrane synthesis and vacuole formation during enlargement of Enterococcus faecalis protoplasts. By varying the timing of novobiocin exposure and removal, the study distinguishes effects on early vacuole formation from effects on continued growth and demonstrates a reversible, replication-dependent control point.

• Fingolimod (FTY720) for Immune-Trafficking Assays

  2026-08-15

  Fingolimod (FTY720) enables a trafficking-first experimental strategy for separating lymphocyte redistribution from T-cell activation, tumor-cell toxicity, and neurobiological signaling. This guide shows how to pair the compound with magnetic bispecific nano-antibody workflows while keeping the combination hypothesis-driven and analytically controlled.

• Maternal Surgery, Calpain, and Offspring Cognition

  2026-08-15

  A 2025 Neuropharmacology study links maternal non-obstetric surgery during pregnancy to offspring cognitive deficits through excessive calpain activity and impaired hippocampal BDNF/TrkB signaling. Its use of both MDL 28170 and a TrkB agonist provides pharmacological evidence that calpain-dependent synaptic and neuronal disruption is functionally relevant, while also defining important limits for translation.

• FPH1 (BRD-6125) Hepatocyte Workflow

  2026-08-14

  FPH1 (BRD-6125) supports expansion and functional evaluation of human hepatocyte models, linking increased cell number with albumin, CYP3A4, and AFP readouts. This workflow shows how to dose, compare, troubleshoot, and interpret the compound without confusing proliferation with maturation.

• BRD4770: G9a Histone Methyltransferase Inhibitor

  2026-08-14

  BRD4770 is a G9a histone methyltransferase inhibitor with a reported enzymatic IC50 of 6.3 μM. Product information links G9a inhibition with reduced intracellular H3K9 methylation, senescence, and suppressed proliferation in PANC-1 cells, while peer-reviewed breast cancer evidence provides pathway context rather than direct BRD4770 validation.

• GW 6471: A Causal Tool for PPARα Studies

  2026-08-13

  GW 6471 is a PPARα antagonist for testing whether receptor activity drives metabolic and toxicological phenotypes. This article translates PFHxS zebrafish evidence into a rigorous, orthogonal assay strategy for cellular metabolism research and lipid homeostasis studies.

• SB 202190: A Translational p38 MAPK Strategy

  2026-08-13

  A thought-leadership framework for using SB202190 (FHPI) to connect p38 biology, patient-derived organoids, pathway-aware assays, and translational decision-making.

• Etoposide (VP-16): From DNA Damage to Translation

  2026-08-12

  A translational framework for using Etoposide (VP-16) to connect topoisomerase II trapping, DNA double-strand breaks, apoptosis, and senescence biomarkers such as cell-surface LAMP1.

446 records 7/30 page Previous Next First page 上5页 678910 下5页 Last page